Arava Will Stay On The Market: FDA Denies Public Citizen Petition For Withdrawal

Aventis says FDA concluded the benefits of the rheumatoid arthritis therapy outweigh the safety risks. Public Citizen cited severe hepatic reactions and a lack of superiority over other therapies in requesting the drug be pulled.